Leadership Overview
Regeneron has 6 executives leading key functions including strategy, scientific research, regulatory compliance, human resources, and operational management.
Driven by a commitment to scientific excellence, Regeneron advances biotechnology through the discovery and commercialization of innovative medicines for serious diseases, aiming to transform patient outcomes globally.
Driven by a commitment to scientific excellence, Regeneron advances biotechnology through the discovery and commercialization of innovative medicines for serious diseases, aiming to transform patient outcomes globally.
Leadership Roles at Regeneron
Antalio Ubalde - Chief Executive Officer
Antalio Ubalde, the Chief Executive Officer at Regeneron, directs the overarching corporate strategy and long-term vision for the biotechnology enterprise. By aligning research initiatives with commercial goals, the Chief Executive Officer ensures the organization maintains a competitive edge in the pharmaceutical market. Antalio Ubalde oversees the integration of proprietary technologies into the drug development pipeline, focusing on high-impact treatments for cancer and inflammatory disorders. This leadership role involves constant collaboration with the Board to optimize resource allocation and drive sustainable growth across North American and international markets. Through rigorous oversight of organizational performance, the Chief Executive Officer maintains focus on the core mission of delivering life-changing therapies. Ultimately, the executive secures the financial and operational health of the company while fostering a culture of scientific innovation and excellence in patient care.
Leonard Schleifer - Co-Chair, President & Chief Executive Officer
Leonard Schleifer, the Co-Chair, President & Chief Executive Officer at Regeneron, architects the strategic framework for the discovery and development of innovative medicines. As the Co-Chair, President & Chief Executive Officer, Schleifer drives the company's scientific agenda, ensuring that proprietary technologies translate into effective treatments for serious diseases. This leadership position involves managing complex relationships with stakeholders and guiding the executive team toward achieving ambitious clinical milestones. Leonard Schleifer monitors the global pharmaceutical landscape to identify emerging opportunities for expansion and therapeutic advancement. By balancing scientific rigor with commercial viability, the executive ensures that the organization remains at the forefront of biotechnology. Through consistent focus on operational efficiency and research breakthroughs, Schleifer supports the delivery of life-changing therapies to patients worldwide, reinforcing the company's reputation as a leader in the pharmaceutical industry.
George Yancopoulos - President & Scientific Office Chief & Co-Founder
George Yancopoulos, the President & Scientific Office Chief & Co-Founder at Regeneron, leads the scientific vision and research efforts that define the company's biotechnology portfolio. As the President & Scientific Office Chief & Co-Founder, Yancopoulos directs the discovery of innovative medicines for conditions such as cancer and inflammatory disorders. This leadership role involves overseeing the proprietary technology platforms that enable the rapid development of life-changing therapies. George Yancopoulos collaborates with research teams to push the boundaries of science, ensuring that the company remains a pioneer in the pharmaceutical industry. By fostering an environment of rigorous inquiry and innovation, the executive drives the development of a robust pipeline of clinical candidates. Through strategic oversight of scientific operations, Yancopoulos ensures that the organization consistently delivers high-quality, impactful treatments to patients, maintaining the company's position as a global leader in medical research.
Kim Brenner - Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality
Kim Brenner, the Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality at Regeneron, manages the critical intersection of regulatory compliance and operational efficiency. Overseeing the global regulatory framework, the Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality ensures that all drug development processes meet stringent safety and quality standards. Kim Brenner directs the integration of patient safety protocols into the broader corporate strategy, facilitating seamless communication between research teams and regulatory bodies. This role involves mitigating risks associated with clinical trials and commercial product distribution across diverse geographic regions. By optimizing internal workflows, the executive supports the rapid advancement of life-changing medicines. Through meticulous attention to detail and strategic planning, Brenner maintains the integrity of the company's product portfolio while ensuring adherence to international health regulations.
Erin Rohr - Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources
Erin Rohr, the Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources at Regeneron, designs the talent acquisition and organizational development strategies necessary to support a high-growth biotechnology firm. As the Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources, Rohr cultivates a workforce capable of executing complex scientific research and commercialization efforts. This leadership role involves aligning human capital initiatives with the company's mission to discover innovative medicines for serious diseases. Erin Rohr manages internal culture and leadership development programs, ensuring that the organization attracts and retains top-tier scientific and operational talent. By implementing scalable HR systems, the executive supports the company's expansion across global markets. Through strategic workforce planning and performance management, Rohr drives organizational agility, enabling the firm to maintain its competitive advantage in the rapidly evolving pharmaceutical sector.
Wrechelle Nantes - Executive Assistant To the Chief Human Resources Officer
Wrechelle Nantes, the Executive Assistant To the Chief Human Resources Officer at Regeneron, coordinates the administrative and operational functions of the human resources department. Supporting the Chief Human Resources Officer, the Executive Assistant To the Chief Human Resources Officer manages complex scheduling, internal communications, and project tracking to ensure the department meets its strategic objectives. Wrechelle Nantes facilitates the flow of information between HR leadership and other executive teams, enabling efficient decision-making regarding talent management and organizational culture. This role involves overseeing the logistics of large-scale recruitment and employee engagement initiatives that support the company's mission of developing life-changing treatments. By streamlining administrative processes, the executive ensures that the HR function remains focused on high-level strategic goals. Through proactive management of departmental resources, Nantes contributes to the overall operational effectiveness of the company's human capital strategy.
Explore Leadership Teams in Manufacturing
Roche is a global pioneer in pharmaceuticals and diagnostics, dedicated to advancing science to improve people's lives through innovative healthcare solutions. The Swiss-based company operates through two primary divisions: Pharmaceuticals and Diagnostics, making it one of the few healthcare companies with leading positions in both areas. Roche's pharmaceutical division focuses on developing and manufacturing prescription medicines across major therapeutic areas including oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The diagnostics division provides a comprehensive range of products and services for early detection, prevention, diagnosis, and management of diseases, spanning laboratory diagnostics, tissue diagnostics, and diabetes care. Roche is committed to personalized healthcare, pioneering the development of targeted therapies and companion diagnostics that enable treatment decisions tailored to individual patients. The company invests heavily in research and development, maintaining a robust pipeline of innovative medicines and diagnostic solutions while collaborating with academic institutions, biotechnology companies, and healthcare partners worldwide. Headquartered in Basel, Switzerland, Roche operates globally with a presence in numerous countries, employing a diverse workforce of scientists, researchers, healthcare professionals, and business experts dedicated to transforming patient care and making a meaningful difference in the fight against serious diseases.
Company Leadership
VA
KK
Sarepta Therapeutics, Inc. is a global commercial-stage biopharmaceutical company founded in 1980 and headquartered in Cambridge, Massachusetts. The company is focused on the discovery, development, and commercialization of precision genetic medicines for rare diseases, with particular leadership in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. Sarepta's multi-platform Precision Genetic Medicine Engine spans gene therapy, RNA-targeted therapeutics, and gene editing modalities. The company holds multiple FDA-approved treatments and maintains a broad pipeline of programs across neuromuscular and central nervous system disorders. Sarepta operates globally with locations across North America, Europe, and Asia, and trades on the NASDAQ under the ticker symbol SRPT.
Company Leadership
ZG
BT
IE
Zydus is a global pharmaceutical company headquartered in Ahmedabad, India. Founded in 1952, the company operates manufacturing sites and research facilities across multiple states in India as well as in the United States and Brazil. Zydus specializes in developing, manufacturing, and distributing pharmaceutical products with a significant global footprint. The company maintains a strong presence in regulated markets including the United States, Europe, Latin America, and South Africa, while also serving numerous emerging markets worldwide. Zydus offers a comprehensive portfolio of pharmaceutical products and services, supported by extensive research and development capabilities.
Company Leadership RR
HS
KT
Bausch Health Companies Inc. operates as a global pharmaceutical and healthcare products company focused on developing, manufacturing, and marketing a broad portfolio of branded pharmaceuticals, generic medicines, over-the-counter healthcare products, and medical devices. The organization works to improve patient health outcomes by delivering therapeutic solutions across multiple medical specialties. Through its research, development, and commercial operations, the company serves healthcare providers, hospitals, pharmacies, and patients across numerous international markets. The company functions as a diversified healthcare enterprise with business segments that address several therapeutic and medical device categories. Its core focus areas include gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and ophthalmology. By maintaining a broad therapeutic portfolio, the organization supports healthcare professionals in diagnosing, managing, and treating a wide range of medical conditions that affect millions of patients globally.
Company Leadership
AF
JS
Frequently Asked Questions Regarding Regeneron Top Executives and Leadership Team
